Evidence for optimal hemoglobin targets in chronic kidney disease

Journal of Nephrology

Volumn 19, Issue 5, 2006, Pages 640-647

  Navaneethan, Sankar D ^a   Bonifati, Carmen ^b   Schena, Francesco P ^b   Strippoli, Giovanni M ^c  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Anemia; Erythropoietin; Hemoglobin targets; Kidney disease; Mortality; Quality of life

Indexed keywords

ALPHA TOCOPHEROL; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERROUS GLUCONATE; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; CREATININE CLEARANCE; DRUG EFFICACY; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LOW DRUG DOSE; PATIENT ATTITUDE; PHYSICAL CAPACITY; QUALITY OF LIFE; TREATMENT OUTCOME;

CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; FEMALE; HEMOGLOBINS; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; RENAL DIALYSIS; RISK FACTORS; THROMBOSIS;

EID: 33947261466     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 2004; 65: 1492-8.
2. Stack AG, Saran R. Clinical correlates and mortality impact of left ven tricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis 2002; 40: 1202-10.
3. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13: 504-10.
4. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-32.
5. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2006; 151: 492-500.
6. Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, Zelikovsky N, Fivush B, Furth S. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 2004; 44: 1017-23.
7. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10: 1309-16.
8. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease. Am J Kidney Dis 2006; 47: S15.
9. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group. Revised European best practice guidelines for the managelnent of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19: S1-47.
10. Pollock C, McMahon L. Biochemical and haemotological targets: guidelines [monograph on the Internet] [cited 2006 Oct 16]. Available from: http://www.cari.org.au/Haemoglobin_rev_aug_2005.pdf.
11. Barrett BJ, Fenton SS, Ferguson B, Halligan P, Langlois S, Mccready WG, Muirhead N, Weir RV. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology. J Am Soc Nephrol 1999; 10: S292-6.
12. Joint Specialty Committee of the RCP, Renal Association. The UK CKD guidelines (2005) [monograph on the Internet] [cited 2006 Oct 16]. Available from: http://www.renal.org/CKDguide/ckd.html.
13. Horl WH. Adjunctive therapy in anaemia mangement. Nephrol Dial Transplant 2002; 17 (Suppl 5): 56-9.
14. Cristol JP, Bosc JY, Badiou S, Leblanc M, Lorrho R, Descomps B, Canaud B. Erythropoeitin and oxidative stress in haemodialysis: benificial effects of vitamin E supplementation. Nephrol Dial Transplant 1997; 12: 2312-7.
15. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE Jr. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-73.
16. Jones M, Schenkel B, Just J. Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality. Int J Cardiol 2005; 100: 253-65.
17. Lebel M, Kingma I, Grose JH, Langlois S. Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J Am Soc Nephrol 1998; 9: 97-104.
18. Moreno F, Vanderrabano F, Aracil FJ, Perez R. Influence of haematocrit on quality of life of haemodialysis patients. Nephrol Dial Transplant 1994; 9: 1034-7.
19. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000; 15: 1425-30.
20. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J, Mittman N. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int 2003; 87: S6-11.
21. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12: 2465-73.
22. Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2004; 15: 3154-65.
23. Cody J, Daly C, Campbell M, Donaldson C, Khan I, Vale L, Wallace S, Macleod A. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients. Cochrane Database Syst Rev 2005; 20: CD003266.
24. Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, Vale L, Wallace S, Macleod A. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005; 20: CD003895.
25. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-90.
26. Furuland H, Linde T, Ahhnen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353-61.
27. Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney Int 1999; 56: 253-60.
28. Brandt JR, Avner ED, Hickman RO, Watkins SL. Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr Nephrol 1999; 13: 143-7.
29. Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Ren Fail 2000; 22: 435-44.
30. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-35.
31. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, Healy H, Kerr P, Lynn K, Parnham A, Pascoe R, Voss D, Walker R, Levin A. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-56.
32. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 1991; 2: 927-36.
33. Bahlmann J, Schoter KH, Scigalla P, Gurland HJ, Hilfenhaus M, Koch KM, Muthny FA, Neumayer HH, Pommer W, Quelhorst E. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contrib Nephrol 1991; 88: 90-106.
34. Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 1992; 60: 390-6.
35. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-85.
36. Lira VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P, Fangman J. Recombinant human erythropoietin treatment in pre-dialysis patients: a double-blind placebo-controlled trial. Ann Intern Med 1989; 110: 108-14.
37. Morris KP, Sharp J, Watson S, Couhhard MG. Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia. Arch Dis Child 1993; 69: 580-6.
38. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25: 548-54.
39. Sikole A, Polenakovic M, Spirovska V, Polenakovic B, Masin G. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 1993; 17: 977-84.
40. Teehan BP, Benz RL, Sigler MH, Brown JM. Early intervention with recombinant human erythropoietin therapy. Semin Nephrol 1990; 10: 28-34.
41. Watson AJ, Gimenez LF, Cotton S, Walser M, Spivak JL. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 1990; 89: 432-5.
42. Canadian Erythropoietin Study Group. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Am J Nephrol 1991; 11: 23-6.
43. Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, Sloand JA, Freedman BI, Williams WW Jr, Shadur CA. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994; 24: 777-84.
44. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-60.
45. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-9.
46. Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Taro P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46: 799-811.
47. Rossert J, Levin A, Roger SD, Horl WH, Fouqueray B, Gassmann-Mayer C, Frei D, McClellan WM. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006; 47: 738-50.
48. Macdougall IC; Steering Committee of the CREATE trial; CREATE Study Group. CREATE: new strategies for early anaemia management in renal insufficiency. Nephrol Dial Transplant 2003; 18: s13-6.